Diabetes News and Research

Latest Diabetes News and Research

New C-COMPASS software opens spatial proteomics and lipidomics to non-coders

A new tool developed by Helmholtz Munich and the German Center for Diabetes Research and the University of Bonn makes spatial proteomics and lipidomics easier to use – no coding required.

4 Dec 2025

Why soybean oil may fuel weight gain

Researchers investigate how soybean oil may disrupt fat metabolism to potentially increase the risk of obesity.

4 Dec 2025

Where you live affects your weight more than you think

Findings reveal a strong link between location and Body Mass Index, emphasizing the need for policies addressing food environments and health disparities.

4 Dec 2025

UCL study reveals the challenges faced by London's night workers

A major new study by UCL researchers has revealed the challenges faced by London's 1.3m night workers, including pay inequality, health problems, transport difficulties, safety concerns and a lack of workplace dignity.

4 Dec 2025

Study opens up new perspectives for targeted care of women with gestational diabetes

An international research team led by the Medical University of Vienna has shown that continuous glucose monitoring (CGM) in women with gestational diabetes can reduce the risk of a newborn with above-average birth weight.

4 Dec 2025

Sweat testing could transform drug monitoring and diabetes care

Innovative sweat sampling techniques could revolutionize diagnostics, offering insights into glucose levels and environmental toxins with minimal discomfort.

4 Dec 2025

Sudden cardiac death risk is sharply elevated in people with diabetes

The risk of sudden cardiac death is higher both for people with type 1 and type 2 diabetes, according to a large study published in the European Heart Journal today (Thursday). The increase in risk is especially noticeable among younger adults.

3 Dec 2025

Diabetes drugs linked to slower frailty progression in older adults

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors-such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)-or glucagon-like peptide-1 (GLP-1) receptor agonists-such as semaglutide (Ozempic) and liraglutide (Victoza)-experience slower progression of frailty over one year compared with those starting other diabetes medications.

3 Dec 2025

Sugar alcohol sorbitol may increase the risk of developing steatotic liver disease

Sweeteners such as aspartame, found in Equal packets, sucralose (Splenda), or sugar alcohols are often seen as healthier alternatives to food with refined sugar (glucose).

3 Dec 2025

Noninvasive blood-glucose monitoring method could replace finger-prick tests for diabetes

A noninvasive method for measuring blood glucose levels, developed at MIT, could save diabetes patients from having to prick their fingers several times a day.

3 Dec 2025

Study finds link between Pg-induced periapical disease and systemic metabolic dysfunction

New study examines the oral pathogen Porphyromonas gingivalis (Pg) and suggests its influence may extend beyond dental tissues.

3 Dec 2025

Settling the creatine safety debate

Research confirms creatine's safety, highlighting misinformation and low-quality supplements as primary concerns over cancer and kidney health risks.

3 Dec 2025

Shingles vaccine may benefit individuals already diagnosed with dementia, new study finds

An unusual public health policy in Wales may have produced the strongest evidence yet that a vaccine can reduce the risk of dementia.

2 Dec 2025

Medical humanities can illuminate the root causes of health disparities, study shows

A new study analyzing dozens of published papers over five decades focusing on health care disparities in Washington, DC, found that those that employed medical humanities approaches identified crucial barriers and opportunities for intervention that quantitative studies often miss.

2 Dec 2025

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

To address the growing global health challenge of obesity, which affects more than 1 billion people, the World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.

2 Dec 2025